Unlock stock picks and a broker-level newsfeed that powers Wall Street.

NYSE - Delayed Quote USD

Revvity, Inc. (RVTY)

91.59
+1.17
+(1.29%)
At close: May 7 at 4:00:02 PM EDT
91.59
0.00
(0.00%)
After hours: May 7 at 5:40:56 PM EDT
Loading Chart for RVTY
  • Previous Close 90.42
  • Open 91.58
  • Bid --
  • Ask --
  • Day's Range 89.80 - 91.92
  • 52 Week Range 88.53 - 129.50
  • Volume 924,065
  • Avg. Volume 1,205,106
  • Market Cap (intraday) 10.796B
  • Beta (5Y Monthly) 1.02
  • PE Ratio (TTM) 37.85
  • EPS (TTM) 2.42
  • Earnings Date Jul 28, 2025 - Aug 1, 2025
  • Forward Dividend & Yield 0.28 (0.31%)
  • Ex-Dividend Date Jul 18, 2025
  • 1y Target Est 124.44

Revvity, Inc. provides health sciences solutions, technologies, and services worldwide. The company's Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and DNA sequencing services. Its Diagnostics segment offers instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. It also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for use in oncology, screening newborns for rare genetic conditions, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific, BioQule, BoBs, chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPatternTM, Evolution Evoya, explorer, Fontus, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Omni Bead Ruptor, Omni Bead Ruptor Elite, Omni Tip, Pannoramic, Panthera Puncher, PG-Seq, PG-Find, PreNAT II, Prime, Protein Clear, ProteinEXact, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord, VICTOR2D, and Zephyr brands. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

www.revvity.com

11,000

Full Time Employees

December 29

Fiscal Year Ends

Recent News: RVTY

View More

Performance Overview: RVTY

Trailing total returns as of 5/7/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

RVTY
17.83%
S&P 500 (^GSPC)
4.26%

1-Year Return

RVTY
11.00%
S&P 500 (^GSPC)
8.55%

3-Year Return

RVTY
37.61%
S&P 500 (^GSPC)
36.57%

5-Year Return

RVTY
0.16%
S&P 500 (^GSPC)
95.45%

Compare To: RVTY

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: RVTY

View More

Valuation Measures

Annual
As of 5/7/2025
  • Market Cap

    10.80B

  • Enterprise Value

    12.98B

  • Trailing P/E

    37.85

  • Forward P/E

    18.52

  • PEG Ratio (5yr expected)

    0.68

  • Price/Sales (ttm)

    4.03

  • Price/Book (mrq)

    1.41

  • Enterprise Value/Revenue

    4.69

  • Enterprise Value/EBITDA

    15.34

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    10.35%

  • Return on Assets (ttm)

    2.09%

  • Return on Equity (ttm)

    3.82%

  • Revenue (ttm)

    2.77B

  • Net Income Avi to Common (ttm)

    296.04M

  • Diluted EPS (ttm)

    2.42

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.14B

  • Total Debt/Equity (mrq)

    43.54%

  • Levered Free Cash Flow (ttm)

    750.5M

Research Analysis: RVTY

View More

Company Insights: RVTY

Research Reports: RVTY

View More

People Also Watch